Exonics - Getting Medicine Into the Brain

After the barrier

Demyelinating disease still lacks true repair

MS, NMOSD, leukodystrophies, and related disorders strip myelin from nerves. Today's care can slow damage or ease symptoms. It does not reliably rebuild the sheath.

Partner with Exonics Meet the team

~2.8MPeople living with MS worldwide

150-200KMS patients in India

98%Brain-targeted drugs that do not get in

Damaged myelin around a nerve fiber — Real myelin ultrastructure reference

Two bottlenecks

Prove repair, then get it across the wall

Remyelination programs fail for two linked reasons: the biology is hard to measure in human models, and almost every payload is turned away at the BBB and BCSFB.

Crossing CNS barriers

More than 98% of brain-targeted molecules face efflux or exclusion at the blood-brain and blood-CSF barriers.

Proving remyelination

The field needs scalable, patient-derived screens built around oligodendrocytes and myelin sheath biology - not proxy models that miss the target.

Therapeutic particle blocked by the CNS barrier — Real CNS barrier tissue reference

Platform

Find what repairs and deliver it where repair is needed

Two products, one path: patient-relevant screening and barrier-aware delivery

NV-Trinity - TRL 3

Targeted nanovesicles for CNS delivery

Nanobody-conjugated, cell-derived nanovesicles designed to move remyelinating payloads across the BBB and BCSFB via receptor-mediated transcytosis.

Transferrin targetingIntegrin targetingCell-derived scaffold

NV-Trinity nanovesicles targeting CNS barrier receptors — Nanovesicle reference microscopy

Nova Morpheus - TRL 2

Patient-derived remyelination screen

Turns patient samples into a quantitative assay for candidates that support oligodendrocytes and myelin sheath formation.

iPSC reprogrammingO4+ enrichmentHigh-throughput imaging

Patient-derived remyelination assay dish — iPSC-derived cell microscopy reference

How it works

Screen the biology, then engineer the route

Nova Morpheus prioritizes repair signals. NV-Trinity carries selected payloads toward the CNS. One workflow connects patient biology to barrier-aware delivery.

01 - Measure

Measure remyelination

Patient-derived cells are guided toward myelin-making biology and screened for repair behavior.

02 - Package

Package the payload

Selected candidates become cargo inside nanobody-conjugated nanovesicles.

03 - Deliver

Target the barriers

Transferrin and integrin targeting support receptor-mediated passage toward CNS lesions.

Why Exonics

Discovery and delivery in one stack

AI-enabled screening, patient-derived neural biology, targeted nanovesicles, and a regenerative focus on myelin - not four separate tools bolted together.

AI screeningPrioritize candidates before human biology testing

Patient biologyOligodendrocyte and myelin models that reflect real disease

Precision deliveryNV-Trinity for BBB and BCSFB transport

Multi-modalitySmall molecules, biologics, peptides, proteins, nucleic acids

Team

Led by scientists and clinicians, externally validated

The team combines CNS biology, nanomedicine, AI-enabled discovery, and clinical insight, with external validation through DBT-WLSE 2026 and a network of collaborators and advisors across AIIMS, IIIT Delhi, IIT Delhi, and industry.

Dr Anusha Aditya

CEO & Co-Founder - DBT-WLSE awardee with expertise in cell biology, nanomedicine, and translational therapeutics

Adrija Aditya

Business Strategist & Co-Founder - MBA, University at Buffalo, with a background in biotechnology and expertise in pharmaceutical business and commercial strategy